GlassScriptPhysician profile
Lori J Kovacevich
NPI 1548499619
$4,884.51
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,164 · 2022: $1,842 · 2023: $879.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $879.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $879.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $840.70 | 2021-2023 | Enhertu |
| Astrazeneca Pharmaceuticals LP | $769.29 | 2021-2023 | Enhertu, Lynparza |
| Seagen INC. | $512.34 | 2021-2023 | Tukysa |
| Merck Sharp & Dohme LLC | $395.45 | 2021-2023 | Keytruda, Lynparza |
| Glaxosmithkline, LLC. | $349.89 | 2021-2023 | Zejula |
| Puma Biotechnology, INC. | $316.32 | 2021-2023 | |
| Eisai INC. | $256.57 | 2021-2023 | |
| Gilead Sciences, INC. | $243.82 | 2021-2023 | Trodelvy |
| Pfizer INC. | $224.50 | 2021-2023 | |
| Amgen INC. | $173.59 | 2021-2022 | |
| Heron Therapeutics, INC. | $104.71 | 2021-2022 | |
| Lilly USA, LLC | $93.55 | 2021 | |
| Myriad Genetic Laboratories, INC. | $50.53 | 2022 | |
| Boston Scientific Corporation | $48.50 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $44.03 | 2021-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $40.42 | 2023 | Opdivo |
| Novartis Pharmaceuticals Corporation | $40.12 | 2022 | |
| Clovis Oncology, INC. | $37.64 | 2021 | |
| Genzyme Corporation | $34.61 | 2022 | |
| Stemline Therapeutics INC. | $32.48 | 2023 | Orserdu |
| Emd Serono, INC. | $32.12 | 2022 | |
| Abbvie INC. | $29.05 | 2023 | |
| Immunogen, INC. | $25.68 | 2023 | Elahere |
| Dova Pharmaceuticals | $22.50 | 2021 | |
| Pharmaessentia USA Corporation | $22.07 | 2023 | Besremi |
| Aadi Bioscience, INC. | $22.01 | 2023 | Fyarro |
| Ipsen Biopharmaceuticals, INC | $21.57 | 2021 | |
| Tersera Therapeutics LLC | $19.68 | 2021 | |
| Eusa Pharma (US) LLC | $19.00 | 2022 | |
| Celgene Corporation | $18.90 | 2023 | Opdualag |
| Mylan Institutional INC. | $15.92 | 2022 | |
| Sobi, INC | $14.35 | 2021 | |
| Janssen Pharmaceuticals, INC | $12.60 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Kovacevich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.